A randomized, double-masked, placebo-controlled parallel study of loteprednol etabonate 0.2% in patients with seasonal allergic conjunctivitis

Ophthalmology

Volumn 106, Issue 2, 1999, Pages 362-369

  Shulman, David G ^a   Lothringer, Larry L ^a   Rubin, Jay M ^a   Briggs, Richard B ^a   Howes, John ^b   Novack, Gary D ^b,c   Hart, Kathryn ^b,d  

^a Pharmos Corp ^*

^b Pharmos Corporation   (United States)

^c PHARMALOGIC DEVELOPMENT INC   (United States)

^d DATA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LOTEPREDNOL ETABONATE;

ADULT; AGED; ALLERGIC CONJUNCTIVITIS; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; INTRAOCULAR HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0033511435     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-6420(99)90077-5     Document Type: Article

References (33)

1. Bodor N. Novel approaches to the design of safer drugs: soft drugs and site-specific chemical delivery systems. Adv Drug Res 1984;13:255-331.
2. Bodor N. Soft drugs: principles and methods for the design of safe drugs. Med Res Rev 1984;4:449-69.
3. Druzgala P, Wu WM, Bodor N. Ocular absorption and distribution of loteprednol etabonate, a soft steroid, in rabbit eyes. Curr Eye Res 1991;10:933-7.
4. Howes J, Novack GD. Failure to detect systemic levels, and effects of loteprednol etabonate and its metabolite, PJ-91, following chronic ocular administration. J Ocul Pharmacol Ther 1998;14:153-8.
5. Dell SJ, Shulman DG, Lowry GM, Howes J. A controlled evaluation of the efficacy and safety of loteprednol etabonate in the prophylactic treatment of seasonal allergic conjunctivitis. Loteprednol Allergic Conjunctivitis Study Group. Am J Ophthalmol 1997;123:791-7.
6. Friedlaender MH, Howes J. A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis. The Loteprednol Etabonate Giant Papillary Conjunctivitis Study Group 1. Am J Ophthalmol 1997;123:455-64.
7. Asbell P, Howes J. A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis. CLAO J 1997;23:31-6.
8. Neumann R, Howes J. Loteprednol etabonate: a novel ocular steroid with improved safety profile. In: Nussenblatt RB, Whitcup SM, Caspi RM, Gery I, eds. Advances in ocular immunology: proceedings of the 6th International Symposium on the Immunology and Immunopathology of the Eye, Bethesda, USA. Amsterdam [Netherlands]; New York: Elsevier, 1994;245-8 (Int'l Congress Ser no. 1068).
9. The Loteprednol Etabonate Post-operative Inflammation Study Group 2. A double-masked, placebo-controlled evaluation of 0.5% loteprednol etabonate in the treatment of post-operative inflammation. Ophthalmology 1998;105:1780-60.
10. Stewart RH, Horwitz B, Howes J, Novack GD, Hart K, Loteprednol Etabonate Post-operative Inflammation Study Group 1. A double-masked, placebo-controlled evaluation of 0.5% loteprednol etabonate in the treatment of post-operative inflammation. J Cataract Refract Surg 1998;24:1480-9.
11. Novack GD, Howes J, Crockett RS, Sherwood MB. Change in intraocular pressure during chronic use of loteprednol etabonate. J Glaucoma 1998;7:266-9.
12. Abelson MB, Smith LM. Levocabastine. Evaluation in the histamine and compound 48/80 models of ocular allergy in humans. Ophthalmology 1988;95:1494-7.
13. Abelson M, Howes J, George M. The conjunctival provocation test model of ocular allergy: utility for assessment of an ocular corticosteroid, loteprednol etabonate. J Ocul Pharmacol Ther 1998 (in press).
14. Ray WA, O'Day DM. Statistical analysis of multi-eye data in ophthalmic research. Invest Ophthalmol Vis Sci 1985;26: 1186-8.
15. Ederer F. Shall we count numbers of eyes or numbers of subjects? Arch Ophthalmol 1973;89:1-2.
16. Newcombe RG, Duff GR. Eyes or patients? Traps for the unwary in the statistical analysis of ophthalmological studies. Br J Ophthalmol 1987;71:645-6.
17. Stewart RH, Smith JP, Rosenthal AL. Ocular pressure response to fluorometholone acetate and dexamethasone sodium phosphate. Curr Eye Res 1984;3:835-9.
18. Ballas Z, Blumenthal M, Tinkelman DG, et al. Clinical evaluation of ketorolac tromethamine 0.5% ophthalmic solution for the treatment of seasonal allergic conjunctivitis. Surv Ophthalmol 1993;38(suppl):141-8.
19. Tinkelman DG, Rupp G, Kaufman H, et al. Double-masked, paired-comparison clinical study of ketorolac tromethamine 0.5% ophthalmic solution compared with placebo eyedrops in the treatment of seasonal allergic conjunctivitis. Surv Ophthalmol 1993;38(suppl):133-40.
20. Azevedo M, Castel-Branco MG, Oliveira JF, et al. Double-blind comparison of levocabastine eye drops with sodium cromoglycate and placebo in the treatment of seasonal allergic conjunctivitis. Clin Exp Allergy 1991;21:689-94.
21. 1 antagonist in patients with allergic conjunctivitis. Allergy 1985;40: 491-6.
22. Cerqueti PM, Ricca V, Tosca MA, et al. Lodoxamide treatment of allergic conjunctivitis. Int Arch Allergy Immunol 1994;105:185-9.
23. Leino M, Carlson C, Jaanio E, et al. Double-blind group comparative study of 2% nedocromil sodium eye drops with placebo eye drops in the treatment of seasonal allergic conjunctivitis. Ann Allergy 1990;64:398-402.
24. Leino M, Ennevaara K, Latvala AL, et al. Double-blind group comparative study of 2% nedocromil sodium eye drops with 2% sodium cromoglycate and placebo eye drops in the treatment of seasonal allergic conjunctivitis. Clin Exp Allergy 1992;22:929-32.
25. Blumenthal M, Casale T, Dockhorn R, et al. Efficacy and safety of nedocromil sodium ophthalmic solution in the treatment of seasonal allergic conjunctivitis. Am J Ophthalmol 1992;113:56-63.
26. Cerqueti PM, Prosio PE, Bosia S, et al. Clobetasone treatment of allergic conjunctivitis: a comparative double blind study. Allergol Immunopathol (Madr) 1993;21:67-70.
27. Ciprandi G, Cerqueti PM, Sacca S, et al. Non-steroidal treatment of pollen-induced conjunctivitis: comparison of different pharmacological protocols. Allergy 1991;46:393-5.
28. Becker B. Intraocular pressure response to topical corticosteroids. Invest Ophthalmol 1965;4:198-205.
29. Armaly MF. Effect of corticosteroids on intraocular pressure and fluid dynamics: I. The effect of dexamethasone in the normal eye. Arch Ophthalmol 1963;70:482-91.
30. Bartlett JD, Horwitz B, Laibovitz R, Howes JF. Intraocular pressure response to loteprednol etabonate in known steroid responders. J Ocul Pharmacol 1993;9:157-65.
31. Friedlaender MH. Conjunctivitis of allergic origin: clinical presentation and differential diagnosis. Surv Ophthalmol 1993;38(suppl):105-14.
32. Reidenberg MM, Lowenthal DT. Adverse nondrug reactions. N Engl J Med 1968;279:678-9.
33. Meyer FP, Troger U, Rohl FW. Adverse nondrug reactions: an update. Clin Pharmacol Ther 1996;60:347-52.